Eli Lilly (LLY) stock remains a promising option despite cutting its fourth-quarter sales guidance by 5%, according to an analyst. The company now expects $13.5 billion in sales for the quarter, which is lower than previously anticipated.
Analysts are still optimistic about Eli Lilly’s growth prospects, with one analyst noting that the weight-loss drug market is “hot” and the company has a substantial revenue opportunity. Zepbound, Eli Lilly’s weight-loss medication, recently won FDA approval to treat obstructive sleep apnea, which could lead to insurance reimbursement for patients.
The analyst also pointed out that Eli Lilly’s pipeline news is expected to be encouraging in 2025, with oral GLP-1 orforglipron Phase 3 results potentially driving financial performance. However, the company’s stock price fell slightly after the revised guidance was announced, closing at 746.74 on Wednesday.
Overall, while Eli Lilly’s sales guidance has been cut, analysts remain upbeat about the company’s potential for growth and revenue in the coming years.
Source: https://www.investors.com/news/technology/eli-lilly-stock-guidance-cut-2025